Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Centre, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Next Previous
X
Search
Trial Profile

An Open-Label, Multi-Centre, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Leuprorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals

    • Most Recent Events

    • 09 Oct 2020 Results of post hoc analysis of data pooled from two post-hoc analysis from two phase 3b trials (NCT00295750-Global and NCT00928434 USA assessing the survival endpoints, published in the Journal of Urology
    • 16 May 2017 Pooled results of trials (NCT00295750 and NCT00928434) presented at the 112th Annual Meeting of the American Urological Association
    • 22 Mar 2014 5-Year results from extension study published in the Urology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top